Recently, Sheyang County, Jiangsu Province, Food and Drug Administration and the Department of Health jointly issued the four measures to strengthen the 2011 adverse drug reactions and medical device adverse event monitoring.
First,digital thermometer strengthen leadership, improve the Medical Device Surveillance Network. Medical institutions should establish a responsible person of the principal leaders of the Medical Device Safety Monitoring Group, township hospitals should include, clinical thermometer including village clinics. Full coverage of high-performance form the monitoring network to Medical Device safety monitoring daily and standardized. Second is to strengthen training and improve the monitoring of the quality of reporting.ear thermometer Third is to strengthen the assessment, establish and improve the rewards and penalties. Medical Device safety monitoring to include the annual assessment work within and report on the discovery of new, rare serious adverse reactions, on the clinical use of drugs and medical devices play an important guiding role, should be promptly rewarded; of serious adverse events (events ) do not report, intended to conceal, and to be criticized, resulting in serious consequences on the people responsible should be severely dealt with. Fourth, focus,digital blood pressure monitor protection of drug use with firearms safety. Medical Device Safety Monitoring 2011, the focus is national and provincial essential medicines list of species, high-risk varieties, vaccines, innovative varieties.
Pharmaceutical sector: ebb tide exposed gold.
Into 2011, since the pharmaceutical sector was hurt, and continued weakness since last December, to continue a substantial adjustment in January pharmaceutical index fell 9.17%, underperforming the Shanghai and Shenzhen 300 Index 7.52%, the former "defensive hero" style no longer exist.
Statistics show that last November 11 to January 26 this year, the amount of the pharmaceutical industry net outflow of funds accumulated more than 17.3 billion yuan; total market capitalization since last November 10 of 1.19 trillion yuan closed down on February 11 when 756.985 billion yuan. And last November 10, the total market value of the pharmaceutical sector even more than the total market value of the real estate industry.
Many analysts pointed out that the pharmaceutical industry, the overall pharmaceutical sector price-earnings ratio is currently near historic lows, valuations are in a reasonable range, some good quality stocks with attractive on a valuation is to choose the identification of gold stocks an excellent point into the room.
Dropped out of the investment value.
Since the end of November 2010 since the pharmaceutical sector there is a clear callback. Pharmaceutical Index fell more than 20% of the largest, by more than last June. January of this year, pharmaceutical stocks rose more or less still, less than 10 stocks to obtain a positive return. Among them, the start of health dollars and buy back 60% of product price increases such as stocks rose Dong EE Jiao front; and last year rose high, high valuations, and high share of the "three high" shares diving medicine, ophthalmology and other decreases in Ireland larger;-HEALTH and some high valuation, high price of new shares and secondary shares have performed poorly.
In addition to the callback because investors worried about the uncertainty of macroeconomic factors, there is regulation of drug prices and other factors, concerns about industry fundamentals. Societe Generale Securities research report pointed out that the pharmaceutical industry, nearly 2 months pharmaceutical sector is mainly due to Shenfutiaozheng Medicine Index 2010, outstanding performance, relative to the Shanghai and Shenzhen 300 Pharmaceutical PE plates once close to 200%, hitting a 10 year high. After nearly two years of bull market, the pharmaceutical sector is currently in a "squeeze bubble" phase.
"Callback gradually restored the investment value of listed companies, including medical devices sub-sector more attractive." Moneta pharmaceutical industry analyst at Sha said. Relatively high valuations in the pre-pressure has been some relief, and promoting the development of the pharmaceutical industry fundamentals, and no major changes. Medicine dropped from a high premium on the plates, squeezing out the "bubble" means the value of high-quality investment timing the arrival of stock.
Debon Securities pointed out that the pressure to resolve the valuation is commonplace, the market is rational and irrational, reason embodied in the "cheap is the last word"; irrational embodied in the "no maximum, only better", medicine is in this section chaos before the trip, and was a lot of investors optimistic about the long-term firm.
To the good macroeconomic environment, the bright has repeatedly confirmed the high annual growth, is the reason people are optimistic about the pharmaceutical industry. A pharmaceutical industry analyst with Shanghai Securities believes that stocks from the "interim high valuation" to enter the lower part of the region in 2011, pharmaceutical stocks will continue to divide. Increased industry concentration, increased production requirements, have led enterprises to focus resources to advantage, leading the best business is the subject of value investing, long-term and event-driven investment opportunities worthy of attention.
Concern was victimizes Ushimata.
Pharmaceutical sector being dispersed or difficult to gather once again the popularity of short-term, the recent weakness in pharmaceutical sector will be the key word. The whole plate down, bring some victimizes the stocks, but also a fall out of the investment opportunities. Medical Unit and the small board and the GEM small-cap stocks represented about two years out with a big bull market, the positive experience with "bubble squeeze" process.
Donghai Securities believes that the rumors of health insurance prices continue to affect the variety of pharmaceutical sector, pharmaceutical sector continued to adjust the rate of close to 6 July last year, the panic down, it should be said that adjustments have been put in place this year from the pharmaceutical industry's expected growth rate and estimates value of the term already has appeal.
Peng Yunliang analysis pointed out that biological agents, medical equipment, medicine health care is a good investment targets, such as medicine prices expected to benefit from the U.S. health medicine, the core competitiveness of outstanding diving medical, release a flow of inventory risk Hualan Biological and so on. Since the API is a cyclical industry, it is difficult to occur long bull stock.
From the current situation, the first-line pharmaceutical stocks such as China Resources Sanjiu Dynamic PE 2011 has been adjusted to 28 times, second and third tier pharmaceutical stocks such as pharmaceutical benefits Bai currently only 25 times earnings, the development of the next few years these companies are relatively OK, and long-term gains worth the wait.
In economic growth, population aging, urbanization, and the four cornerstones of the new medical reform and other support, China's pharmaceutical industry is moving into the golden years of rapid growth. Both as one of the few two characteristics of consumption and new technology industries for a long time in the future, the pharmaceutical sector will continue to be investor attention. Future performance in the annual report under the impetus of these varieties will be victimizes bottom out.
Chinese herbal medicines or restore the rally.
In January, in addition to pharmaceutical sector continues to Shenfudiaozheng, the "frozen north south dry" weather triggered a new round of price gains of Chinese herbal medicines, but also caused a lot of attention.
Varieties of Chinese herbal medicines in 2010 prices rose almost across the board, many Chinese herbal medicine manufacturers earn pours. One or more than 100% up to 151 varieties, more extreme varieties such as heterophylla even from 21 yuan / kg up to 300 yuan / kg, others such as Radix, Panax, psoralen, Campanulaceae, bergamot, and other varieties also rose over 500%.
It is understood that the recent Hebei, Henan, Shandong, Shanxi and other provinces in varying degrees of drought. Affected by this, production has declined in some Chinese herbal medicines, the price is to resume its rally. Salvia, the hawthorn plant was severely affected, this cut is inevitable; peasant households species of Cassia and licorice are also severely affected.
In this context, the price of medicinal herbs such as Panax started to rise from the lows last year, more than 20% gain. CIC Securities Research report points out that since the Yin Xinan last spring drought has prompted notoginseng, safflower, etc. set off a round of crazy prices, if the drought continues to intensify, not expected to rule out the honeysuckle and other major traditional Chinese medicine prices to regain a new a rally.
Chinese herbal medicine prices with pharmaceutical companies for lower prices, it can be said of the two sword hanging over his head. Secondary market prices for drugs and other risks that general policy concerns. Industrial Securities, believes that "price may be a pseudo-proposition," the market risk for the policy need not be too worried, Development and Reform Commission on the adjustment of the maximum retail price, is actually lower drug prices for a formal confirmation.
Some experts pointed out that the pharmaceutical industry itself is a "policy market" under the policy guidance in the current industry's competitive environment, the performance of listed companies will not be back to the industry from 2005 to 2006 low; each policy for the industry sector due to medical crash, is a good opportunity to pick up high-quality chips, high-quality long-term pharmaceutical stocks will perform "spiral" up trend.
Societe Generale Securities believes that the pricing remains the exclusive advantage of varieties, prices of medicine by traditional Chinese medicines, price cuts may be small. If less than 15% decline, has little effect on the industry. Price or in the main varieties of anti-infective drugs and a large quantity of drugs and other cardiovascular drugs category.
For the secondary market, the policy more of a psychological disturbance factors, such as the current policy of drug prices is expected to not fully release the negative, perhaps when the price of the "boots" landing, the market has digested the relevant negative factor. Medical reform in the new trend, a number of supporting the implementation of policies and direction of the industry reshuffle is necessary intensive thrust, although it may bring short-term pain, but will lead to strong Hengqiang leading companies, the real value of investment in a number of listed medicine company will also continue to emerge.